Article Details
Retrieved on: 2022-06-07 16:25:27
Tags for this article:
Click the tags to see associated articles and topics
Excerpt
Those individuals switching to ofatumumab frequently had been taking other monoclonal antibodies (36%) — most often ocrelizumab (21%).
Article found on: www.neurologyadvisor.com
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here